skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Long-term clinical followup of subjects in a BNCT protocol

Journal Article · · Transactions of the American Nuclear Society
OSTI ID:426310
 [1]; ;  [2]
  1. Massachusetts Inst. of Technology, Cambridge, MA (United States)
  2. New England Deaconess Hospital, Boston, MA (United States); and others

Four subjects underwent a phase-I boron neutron capture therapy (BNCT) protocol between September 1994 and September 1995. Three of the subjects were women; the range of ages was 61 to 80 yr; three subjects were of Caucasian origin, one (a male) was of Haitian origin. The subjects had subcutaneous metastatic melanoma nodules on their lower extremities but no other known sites of involvement. All four subjects are currently alive and between 6 and 18 months post-BNCT. The subjects each received 400 mg/kg of 1,BPA orally as a {open_quotes}test{close_quotes} dose for pharmacokinetic study purposes, followed by four equal doses of 400 mg/kg of a few hours prior to each of four neutron irradiation fractions. The first three subjects received total maximum normal tissue doses of 1000 relative biological effectiveness (RBE)-cGy, while the fourth received 1250 RBE-cGy. The associated macroscopic tumor doses were typically 25 to 35% higher due to the elevated uptake of boron in tumor compared to normal tissue. Three of the four subjects (including the one at the higher dose level) manifested no skin or other observable normal tissue reactions to the BNCT; one subject (at the 1000 RBE-cGy dose level) manifested a very clear skin reaction, consisting of redness and slight blistering of the skin over the tumor nodules, a couple of days following the fourth radiation fraction, which resolved within 1 to 2 weeks. Two of the four subjects (at the 1000 RBE-cGy dose level) manifested clear tumor regression in those modules that were included in the 15-cm-diam circular radiation field but not in those nodules outside the perimeter of the radiation field. Thus far, there have been no reversals to these effects.

OSTI ID:
426310
Report Number(s):
CONF-961103-; ISSN 0003-018X; TRN: 96:006307-0030
Journal Information:
Transactions of the American Nuclear Society, Vol. 75; Conference: Winter meeting of the American Nuclear Society (ANS) and the European Nuclear Society (ENS), Washington, DC (United States), 10-14 Nov 1996; Other Information: PBD: 1996
Country of Publication:
United States
Language:
English

Similar Records

Clinical phase-I study of Na[sub 2]B[sub 12]H[sub 11]SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT)
Journal Article · Wed Mar 30 00:00:00 EST 1994 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:426310

Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial
Journal Article · Sun May 01 00:00:00 EDT 2016 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:426310

A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas
Conference · Tue Dec 31 00:00:00 EST 1996 · OSTI ID:426310